PDCD1 and neoplasm: In addition to clinical factors and radiological response, detailed knowledge of the patient’s immune status of peripheral blood is needed to evaluate the efficacy of combination anti-PD-1/PD-L1 treatment, and tumor immunogenicity score is evaluated as a predictor of immune checkpoint inhibitor response (31, 32).